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London NW7 1AA, United Kingdom.Understanding how p53 is able to speciﬁcally respond to particular stress signals and regulate many
different signalling pathways remains a challenge. Several studies have demonstrated that p53’s
interactions with different protein partners are essential for it to be able to coordinate speciﬁc
responses. In particular, the apoptotic pathway is regulated by p53 in cooperation with the Apopto-
sis Stimulating Proteins of p53 (ASPP) proteins. In this study, we showed that the ASPP proteins are
able to bind and cooperate with p300, a well deﬁned co-factor of p53, to selectively regulate p53’s
transcriptional activity on promoters such as p53-inducible gene 3 but not on p21waf1. This is
the ﬁrst demonstration that the ASPPs can function together with p300 in regulating the transcrip-
tional activity of p53.
Structured summary of protein interactions:
ASPP2 physically interacts with p300 and p53 by anti bait coimmunoprecipitation (View interaction)
iASPP physically interacts with p300 by anti bait coimmunoprecipitation (View interaction)
iASPP physically interacts with p300 and p53 by anti bait coimmunoprecipitation (View interaction)
ASPP2 physically interacts with p300 by anti bait coimmunoprecipitation (View interaction)
ASPP1 physically interacts with p300 by anti bait coimmunoprecipitation (View interaction)
ASPP1 physically interacts with p300 and p53 by anti bait coimmunoprecipitation (View interaction)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
First discovered 30 years ago, p53 is an evolutionarily conserved
tumour suppressor protein that is absent or mutated in 50% of hu-
man cancers [1,2]. Primarily acting as a transcription factor, p53
has a wide range of different functions, and regulates many diverse
signalling pathways in mammalian cells [3]. Indeed, the majority
of the p53 mutations that are linked to cancer affect its DNA bind-
ing domain (80% of all mutations; www.p53.iarc.fr). A recent study,
based on a combination of ChIP and paired-end diTag (PET)
sequencing, predicted that p53 is able to bind to at least 542 differ-
ent loci, highlighting the vast number of genes that it regulates [4].
One of the most challenging unresolved questions is, therefore,chemical Societies. Published by E
of p53; Bax, Bcl-2-associated
aired-end diTag; PIG3, p53-
l Research (NIMR), Medical
Neurobiology, The Ridgeway,how does p53 decide to activate or repress one signalling pathway
more than another? Current evidence suggests that p53 integrates
stress signals via post-translational modiﬁcations, adapting its re-
sponse by coordinating with different protein partners, thus en-
abling the p53-mediated stress response to be tissue speciﬁc [3,5].
Recent studies have emphasised the role of p53’s co-factor pro-
teins in coordinating its response to stress signals. One of the ﬁrst
p53 co-factors identiﬁed was p300, an acetyl transferase that gen-
erally enhances p53’s transcriptional activity. More recently, the
Apoptosis Stimulating Protein of p53 (ASPP) family of proteins
was found to represent another type of co-factor that can selec-
tively regulate p53’s activity. The ASPP family is composed of three
members: ASPP1 and ASPP2, which are p53 activators; and iASPP,
one of p53’s most conserved inhibitors [6–8]. The p53-dependent
apoptotic response has been demonstrated to be modulated by
the ASPPs, which have also been shown to be involved in tumouri-
genesis [9,10].
Acetylation of p53 has been reported to modulate its transcrip-
tional activity [11,12]. In particular, p300 was reported to inﬂuence
the stability of p53 once it is bound to DNA [13]. However, p300
does not exhibit any known promoter selectivity. Since the ASPPlsevier B.V. All rights reserved.
Fig. 1. The ASPP proteins synergise with p53 and p300 to activate expression of the PIG3 reporter gene in SaOS-2 cells. All transfections were done in duplicate. Cells were
harvested 48 h after transfection for luciferase assay with the PIG3Luc 17mer reporter (A and C) or with the p21Luc reporter (B). Reporter values (control) were set to 1 to
allow estimation of the effects of p300 and the ASPP proteins. (A) Representative of the average of ﬁve independent experiments with standard deviation indicated. (B and C)
Represent the average of three independent experiments with standard deviation indicated. (D) Analysis of total cell lysate after luciferase assay by Western blot; equal
amounts of protein were loaded onto gels and blotted for p300 (RW128), V5 (for the detection of the ASPP proteins), p53 (DO-1) and b-tubulin (loading control).
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p53 on promoters like Bcl-2-associated X protein (Bax) and p53-
inducible gene 3 (PIG3), but not on p21waf1 and murine double
minute 2 (mdm2), we investigate here whether the ASPP family
can cooperate with p300 to selectively regulate the activity of p53.
2. Materials and methods
2.1. Cell lines, antibodies, plasmids and reagents
H1299, SaOS-2 and U2OS cells were cultured in DMEM (Lonza)
supplemented with 2 mM L-glutamine (Gibco), 200 units/ml peni-
cillin/streptomycin (Gibco) and 10% (v/v) foetal calf serum, in
ﬂasks maintained in an incubator at 37 C in the presence of 10%
CO2. Antibodies were purchased for b-tubulin (ab6046, Abcam),
p300 (RW128, Upstate), V5 (MCA1360, Serotec) and Ku80
(ab3107, Abcam). Antibodies for p53 (DO-1), ASPP1 (LX54.2 and
N8), ASPP2 (LX54.10 and BP77) and iASPP (LX49.3 and N1) were
from ascites. Wild type pcDNA3.1(-)/p53, pcDNA3.1/ASPP1,
pcDNA3.1/ASPP2 and pcDNA3.1/iASPP were from Samuels-Lev
et al. pcDNA3.1/p300 and pcDNA3.1/pCAF were gifts from Prof.W. Gu. The PIG3Luc 17mer reporter gene and the p21Luc reporter
gene were gifts from Prof. M. Dobbelstein and Prof. B. Vogelstein,
respectively. The Renilla-TK-Luciferase (cat #E2241) and luciferase
assay kit (cat #E1910) were purchased from Promega, UK.
2.2. Gene reporter assay
6  105 SaOS-2 cells were plated in 6 cm dishes and transfected
with 50 ng pcDNA3.1/p53, 2 lg pcDNA3.1/p300, 2 lg pcDNA3.1/
pCAF, 4 lg pcDNA3.1/ASPP1, 4 lg pcDNA3.1/ASPP2 and 250 ng
pcDNA3.1/iASPP, as indicated using the CaCl2 method [23]. All
samples were co-transfected with 30 ng of Renilla-TK-Luciferase,
and 1 lg of PIG3Luc 17mer reporter or 1 lg of p21Luc reporter.
All transfections were done in duplicate. Cells were harvested
48 h after transfection to perform a luciferase assay following the
manufacturer’s instructions (Promega).
2.3. Immunoblotting and immunoprecipitation
For immunoblotting, cells were washed three times with 1
cold PBS and lysed with NET/NP-40 (150 mM NaCl, 50 mM Tris–
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protease inhibitor (Complete, Roche). The cells were scraped with
a sterile disposable cell scraper (Greiner), transferred to an eppen-
dorf tube, centrifuged at 14 000 rpm, at 4 C for 30 min and blotted
as described in Gillotin et al. (2010). For immunoprecipitation (IP),
1000 lg of cell lysate was precleared with 30 ll of protein G Se-
pharose (50% slurry in PBS) for 30–60 min at 4 C on an eppendorf
rotating wheel. The lysate was centrifuged at 2500 rpm for 2 min
and the supernatant removed to a fresh tube. One to four microli-
tres of antibody (ASPP1, N8; ASPP2, BP77; iASPP, N1) and 30 ll
protein G Sepharose (50% slurry in PBS) was then added to the
pre-cleared lysate. The mixture was left on an eppendorf rotating
wheel overnight at 4 C. Immunocomplexes were collected by cen-
trifugation at 2500 rpm for 3 min and the supernatant discarded.
Beads were washed with three successive changes of lysis buffer.
After removing as much residual supernatant as possible, IP beads
were mixed with 30 ll of 5 sample buffer and heated at 95 C for
5 min. The beads were then centrifuged at 14 000 rpm for 15 s and
all or part of the sample loaded onto an SDS–polyacrylamide gel.
The separated proteins were then subjected to Western analysis.
3. Results
To understand whether p300 can cooperate with the ASPP
proteins in gene transcription, we performed reporter gene assays
using the pro-apoptotic PIG3-Luciferase reporter which contains
the PIG3 promoter, a gene identiﬁed in p53 induced apoptosis in
SaOS-2 cells, a cell line in which p53 is deleted (Fig. 1A). As
previously published, co-expressing p53 with either ASPP1 or
ASPP2 enhanced the PIG-3 reporter activity over transfection of
p53 alone [6]. Under the conditions used, iASPP had a moderate ef-
fect on the inhibition of p53, whereas p300 alone had little effect
on the transcriptional activity of p53. When ASPP1 or ASPP2 wereFig. 2. Co-immunoprecipitation of the ASPP proteins. H1299 and U2OS cells were left
(RW128), ASPP1 (LX54.2), ASPP2 (LX54.10), iASPP (LX49.3), p53 (DO-1) and Ku80
Immunocomplexes were probed for p300 (RW128), ASPP1 (LX54.2) and p53 (DO-1) (top r
and for p300 (RW128), iASPP (LX49.3) and p53 (DO-1) (bottom right panel).co-transfected with p53 and p300 simultaneously, we observed a
synergistic effect between the three proteins in activating the
PIG3 reporter gene over the co-transfection of ASPP1 or ASPP2 with
p53. In contrast, however, co-transfection of iASPP and p300 main-
tained the modest inhibitory effect of iASPP and did not increase it.
To investigate whether the ASPP proteins could maintain their
ability to selectively enhance p53’s transcriptional activity in the
presence of p300, we tested the effect of the ASPP proteins and
p300 on the p21waf1-Luciferase reporter which contains the p21
promoter, a cyclin dependent kinase inhibitor (Fig. 1B). In agree-
ment with our current working model [6], we were unable to ob-
serve any synergy between ASPP1, ASPP2, p300 and p53 in
transactivating the p21 reporter gene. Next, we tested whether
the synergistic effect between p300 and ASPP1 or ASPP2 could be
generalised to other acetyl-transferases. The p300-related acetyl-
transferase pCAF was used in a similar assay, using the PIG3-Lucif-
erase reporter gene (Fig. 1C). Unlike p300, ASPP1 and ASPP2 were
not able to cooperate with pCAF, suggesting a speciﬁc level of reg-
ulation between the ASPP proteins and p300. The observed differ-
ences in the activity of the reporter genes were not due to
differences in the expression levels of p53 (conﬁrmed by Western
analysis) (Fig. 1D). All these results suggest that ASPP1 and ASPP2
can cooperate with p300 to enhance the transcriptional activity of
p53, and that this synergy is promoter speciﬁc.
The binding between p53 and p300 is well established, and
p300 binding sites have been reported at both the N- and C-termini
of p53 [14]. To investigate how the ASPP proteins and p300 may
cooperate, we investigated whether the ASPP proteins reside in
the same protein complex as p300 and p53. We used U2OS cells
expressing wild type p53, and compared them to H1299 cells
which do not express p53, untreated or treated with doxorubicin
to stimulate p53. ASPP1, ASPP2 and iASPP were immunoprecipi-
tated (Fig. 2) and p300 and p53 visualised by Western blot. Theuntreated or treated with doxorubicin (2 lM) overnight. Expression levels of p300
(loading control) (left panel) were determined by Western blot as described.
ight panel), for p300 (RW128), ASPP2 (LX54.10) and p53 (DO-1) (middle right panel)
Fig. 3. Model for the cooperation between p53, the ASPP proteins and p300. Interaction of iASPP with the complex p53/p300 would favour cell survival, whereas interaction
with ASPP1 or ASPP2 would favour cell death.
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gether in U2OS cells, with or without DNA damage. Importantly,
ASPP proteins were also found to complex with p300 in H1299
cells that are null for p53. These results suggest that the ASPPs
may cooperate with p300 to regulate the transcriptional activity
of p53, by forming an ASPP/p300/p53 complex in cells. However,
p53 is not absolutely required for ASPP to bind p300.
4. Discussion
Taken together, the results shown in this study suggest that
ASPP1 and ASPP2 are able to bind and cooperate synergistically
with p300 to enhance p53’s transcriptional activity. Interestingly,
this synergistic effect of ASPP1 or ASPP2/p300 on the transcrip-
tional activity of p53 maintains the ASPPs’ promoter selectivity.
Under the same conditions, the interaction between p300 and iAS-
PP had less of an effect on iASPP’s inhibitory activity on p53
transcription.
While ASPP2 has been shown to localise on promoters such as
Bax in vivo [6,8], a biochemical study using puriﬁed recombinant
proteins containing the DNA binding domain of p53 and the C-ter-
minus of ASPP2 showed that the co-localisation of p53 and ASPP2
on DNA is mutually exclusive [15]. Precisely how the ASPP proteins
are involved in p53 target promoter selectivity remains unknown.
However, it is known that p53 requires the two other p53 family
members, p63 and p73, to induce apoptosis [16]. In addition,
ASPP1 and ASPP2 are common activators of the three p53 family
members [17], binding directly to their DNA binding domains
[15,18,19]. p300’s acetylation activity has previously been shown
to be more active on p53 when p53 is bound to DNA [13,20]. The
majority of the known apoptosis-related target genes of p53 have
weak p53 binding sites, in contrast to promoters such as p21 and
MDM2, which bind p53 with high afﬁnity [21]. It is interesting to
note that all of the promoters that the ASPP family is able to en-
hance are p53 target promoters, that have weak p53 afﬁnity bind-
ing sites. Thus, it is possible that ASPP1 and ASPP2 may help to
recruit p300 to such weak afﬁnity sites, and consequently increase
the activation of p53 in collaboration with p63 and p73. In con-
trast, iASPP preferentially binds to p53’s proline rich region while
ASPP1 and ASPP2 mostly bind to p53’s DNA binding domain [22].
Moreover, p53’s proline rich region is required for p300 to acety-
late and stabilize p53 when bound to DNA [13], which suggests
that iASPP and p300 may compete against each other to inﬂuence
p53’s activity when it is bound to chromatin. This supports the
data presented here, and may explain why iASPP’s inhibition of
p53 does not seem to be modiﬁed by p300, despite the fact thatthey are able to bind to each other in the presence or absence of
p53 (Fig. 3). Future studies are required to illustrate whether p63
and/or p73 are required for the ASPP proteins to modulate p53’s
transcriptional activity. In particular, an investigation of the inter-
actions between p63 and p73 with iASPP may prove to be relevant
to the design of new compounds for cancer therapy, which act by
alleviating the inhibition of apoptosis.
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